SCHEMBL6164487

SCHEMBL6164487

N#Cc1cccc(NC(=O)Nc2ccccc2-c2cccc(C#N)c2)c1

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 3/20 0.62
ALDH1A1 P00352 3/20 0.62
MEN1 O00255 2/20 0.62
KMT2A Q03164 2/20 0.62
GAA P10253 3/20 0.54
ALOX15 P16050 2/20 0.54
HSD17B10 Q99714 2/20 0.54
CASP7 P55210 1/20 0.54
CXCR2 P25025 2/20 0.53
CXCR1 P25024 1/20 0.53
KDR P35968 1/20 0.53
NPC1 O15118 1/20 0.52
RAB9A P51151 1/20 0.52
SMN1; SMN2 Q16637 1/20 0.52
KDM4E B2RXH2 2/20 0.51
HTT P42858 1/20 0.50
LMNA P02545 1/20 0.50
CCR3 P51677 2/20 0.49
CHRM3 P20309 1/20 0.49
BLM P54132 1/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6164394 0.91 MAPT (0.64) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL6165775 0.91 MAPT (0.68) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL5113281 0.83 CHRM3 (0.53) MAPTALDH1A1MEN1KMT2AHSD17B10
SCHEMBL29580531 0.83 MAPT (0.87) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL30606801 0.83 MAPT (0.87) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL17079595 0.81 DDX3X (0.73) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL8981857 0.80 CHRM3 (0.53) NPC1RAB9AKDM4ECHRM3
SCHEMBL6163176 0.78 MAPT (0.56) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL7248947 0.77 MAPT (1.00) MAPTALDH1A1MEN1KMT2AGAA
SCHEMBL6165957 0.77 LMNA (0.64) MAPTALDH1A1MEN1KMT2AHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1254136-A4 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD (KR) 2005-06-01 EP disclosed
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof LG CHEM INVESTMENT LTD. (KR) 2003-04-03 US disclosed
EP-1254136-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG Chem Investment, Ltd. (KR) 2002-11-06 EP disclosed
WO-2001055146-A1 FACTOR Xa INHIBITORS WITH ARYL-AMIDINES AND DERIVATIVES, AND PRODRUGS THEREOF LG CHEM INVESTMENT LTD. (KR) 2001-08-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030065176-A1 Factor xa inhibitors with aryl-amidines and derivatives, and prodrugs thereof F2, F12, TFPI MAPT 4356/4885ALDH1A1 1388/4885MEN1 3229/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.